Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative research at NIMHANS.

The United States Huntington's Disease Treatment Market is set to expand significantly, with an expected CAGR of 15.22% from ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT ®-HD2 study demonstrating an established long-term safety ...

Researchers announce breakthrough results for AMT-130, the first disease-modifying treatment for Huntington's disease, with ...

However, in late September 2025, scientists successfully treated Huntington’s for the first time in a ground-breaking study.

SOM Biotech, a clinical-stage company dedicated to the discovery and development of innovative therapies for rare central nervous system disorders, announces today that it has received the final ...

People with Huntington’s disease often lose control over their voluntary movements, which can affect daily functioning more severely than the involuntary jerks caused by chorea. Difficulties with ...

Last month, “historic positive results” from uniQure’s gene therapy snapped the Huntington’s community out of years of failure. As the biotech prepares to submit for FDA approval, BioSpace looks at ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Analysts are estimating that Neurocrine Biosciences will report an earnings per share (EPS) of $1.87. Neurocrine Biosciences ...